NCT04613297

HLA-G Immuno-Inhibitor Checkpoint Study in Patients With COVID-19 Infection: Molecular and Cellular Assessment

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 91 (actual)
• Sponsor: Hopital Foch · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of the research is to study the immune checkpoint linked to the HLA-G molecule in the dysregulation of the control of COVID-19 infection.

Detailed description

Single-center, prospective, open-ended, interventional study with minimal risks and constraints. Patients will be divided into 3 groups: patients not infected with COVID-19, patients infected with COVID-19 not hospitalized, patients infected with COVID-19 hospitalized.

Conditions

• Covid19

Interventions

Type	Name	Description
OTHER	Baseline and during hospitalization blood samples	Blood sample will be performed at the inclusion visit for all patient and for the hospitalized COVID-19 infected patients, extra-blood samples will be performed : * at day 3 * day 5 and * In case of aggravation * At the discharge from hospital
OTHER	Baseline blood sample	Blood sample will be performed at the inclusion visit only

Timeline

• Start date: 2020-10-19
• Primary completion: 2022-07-19
• Completion: 2022-07-19
• First posted: 2020-11-03
• Last updated: 2022-08-03

Locations

1 site across 1 country: France